vs

Side-by-side financial comparison of Accelerant Holdings (ARX) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Accelerant Holdings is the larger business by last-quarter revenue ($267.4M vs $142.0M, roughly 1.9× Oncology Institute, Inc.). Oncology Institute, Inc. runs the higher net margin — -5.3% vs -511.9%, a 506.6% gap on every dollar of revenue.

Accelerant Holdings is a global specialty insurance and reinsurance technology platform that leverages advanced data analytics and risk assessment tools to support insurance carriers, managing general agents, and underwriting partners. It delivers tailored risk solutions, streamlines underwriting workflows, and serves commercial and specialty insurance segments across North America and European markets.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

ARX vs TOI — Head-to-Head

Bigger by revenue
ARX
ARX
1.9× larger
ARX
$267.4M
$142.0M
TOI
Higher net margin
TOI
TOI
506.6% more per $
TOI
-5.3%
-511.9%
ARX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ARX
ARX
TOI
TOI
Revenue
$267.4M
$142.0M
Net Profit
$-1.4B
$-7.5M
Gross Margin
Operating Margin
-507.7%
-4.9%
Net Margin
-511.9%
-5.3%
Revenue YoY
41.6%
Net Profit YoY
43.0%
EPS (diluted)
$-6.99
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARX
ARX
TOI
TOI
Q4 25
$142.0M
Q3 25
$267.4M
$136.6M
Q2 25
$219.1M
$119.8M
Q1 25
$104.4M
Q4 24
$100.3M
Q3 24
$99.9M
Q2 24
$98.6M
Q1 24
$94.7M
Net Profit
ARX
ARX
TOI
TOI
Q4 25
$-7.5M
Q3 25
$-1.4B
$-16.5M
Q2 25
$8.8M
$-17.0M
Q1 25
$-19.6M
Q4 24
$-13.2M
Q3 24
$-16.1M
Q2 24
$-15.5M
Q1 24
$-19.9M
Operating Margin
ARX
ARX
TOI
TOI
Q4 25
-4.9%
Q3 25
-507.7%
-5.9%
Q2 25
10.2%
-9.4%
Q1 25
-9.5%
Q4 24
-11.9%
Q3 24
-13.9%
Q2 24
-16.6%
Q1 24
-19.0%
Net Margin
ARX
ARX
TOI
TOI
Q4 25
-5.3%
Q3 25
-511.9%
-12.1%
Q2 25
4.0%
-14.2%
Q1 25
-18.8%
Q4 24
-13.1%
Q3 24
-16.1%
Q2 24
-15.7%
Q1 24
-21.0%
EPS (diluted)
ARX
ARX
TOI
TOI
Q4 25
$-0.04
Q3 25
$-6.99
$-0.14
Q2 25
$0.04
$-0.15
Q1 25
$-0.21
Q4 24
$-0.14
Q3 24
$-0.18
Q2 24
$-0.17
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARX
ARX
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$1.6B
Total DebtLower is stronger
$121.9M
Stockholders' EquityBook value
$676.1M
$-15.7M
Total Assets
$7.9B
$164.7M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARX
ARX
TOI
TOI
Q4 25
Q3 25
$1.6B
Q2 25
$1.4B
Q1 25
Q4 24
Q3 24
Q2 24
$9.9M
Q1 24
$29.8M
Total Debt
ARX
ARX
TOI
TOI
Q4 25
Q3 25
$121.9M
Q2 25
$126.7M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ARX
ARX
TOI
TOI
Q4 25
$-15.7M
Q3 25
$676.1M
$-12.3M
Q2 25
$346.2M
$-9.0M
Q1 25
$5.1M
Q4 24
$3.6M
Q3 24
$15.5M
Q2 24
$29.2M
Q1 24
$41.3M
Total Assets
ARX
ARX
TOI
TOI
Q4 25
$164.7M
Q3 25
$7.9B
$163.6M
Q2 25
$7.5B
$159.8M
Q1 25
$164.0M
Q4 24
$172.7M
Q3 24
$179.2M
Q2 24
$179.6M
Q1 24
$204.5M
Debt / Equity
ARX
ARX
TOI
TOI
Q4 25
Q3 25
0.18×
Q2 25
0.37×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARX
ARX
TOI
TOI
Operating Cash FlowLast quarter
$73.9M
$3.2M
Free Cash FlowOCF − Capex
$2.2M
FCF MarginFCF / Revenue
1.5%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARX
ARX
TOI
TOI
Q4 25
$3.2M
Q3 25
$73.9M
$-12.6M
Q2 25
$309.3M
$-10.2M
Q1 25
$-5.0M
Q4 24
$4.2M
Q3 24
$819.0K
Q2 24
$-15.7M
Q1 24
$-15.9M
Free Cash Flow
ARX
ARX
TOI
TOI
Q4 25
$2.2M
Q3 25
$-13.2M
Q2 25
$-11.4M
Q1 25
$-5.3M
Q4 24
$2.4M
Q3 24
$417.0K
Q2 24
$-17.5M
Q1 24
$-16.5M
FCF Margin
ARX
ARX
TOI
TOI
Q4 25
1.5%
Q3 25
-9.7%
Q2 25
-9.5%
Q1 25
-5.1%
Q4 24
2.4%
Q3 24
0.4%
Q2 24
-17.7%
Q1 24
-17.4%
Capex Intensity
ARX
ARX
TOI
TOI
Q4 25
0.7%
Q3 25
0.4%
Q2 25
1.0%
Q1 25
0.3%
Q4 24
1.8%
Q3 24
0.4%
Q2 24
1.9%
Q1 24
0.6%
Cash Conversion
ARX
ARX
TOI
TOI
Q4 25
Q3 25
Q2 25
35.15×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARX
ARX

Underwriting Segment$117.6M44%
Exchange Services Segment$85.0M32%
Other$64.8M24%

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons